Caffeine is the most widely used psychostimulant in Western countries, with antioxidant, anti-inflammatory and anti-apoptotic properties. In Alzheimer's disease (AD), caffeine is beneficial in both men and women, in humans and animals. Similar effects of caffeine were observed in men with Parkinson's disease (PD); however, the effect of caffeine in female PD patients is controversial due to caffeine's competition with estrogen for the estrogen-metabolizing enzyme, CYP1A2. Studies conducted in animal models of amyotrophic lateral sclerosis (ALS) showed protective effects of A 2A R antagonism. A study found caffeine to be associated with earlier age of onset of Huntington's disease (HD) at intakes >190 mg/d, but studies in animal models have found equivocal results. Caffeine is protective in AD and PD at dosages equivalent to 3-5 mg/kg. However, further research is needed to investigate the effects of caffeine on PD in women. As well, the effects of caffeine in ALS, HD and Machado-Joseph disease need to be further investigated. Caffeine's most salient mechanisms of action relevant to neurodegenerative diseases need to be further explored.
| 273
KOLAHDOUZAN AND HAMADEH consumed >4 cups of coffee, concluding that three cups/d of coffee were the most effective in reducing cognitive decline. 10 In addition, a 21-year follow-up study found that moderate consumption (3) (4) (5) cups/d) was associated with lower risk of dementia in men (OR=0.27, CI=0.08-0.89) and women (OR=0.51, CI=0.17-1.52), compared to low consumption (0-2 cups/d). Among men, the risk of developing dementia was lower when consuming high levels of coffee (>5 cups) compared to low coffee consumption (OR=0.36, CI=0.13-0.97).
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Caffeine can inhibit lipid peroxidation and reduce reactive oxygen species (ROS) production. 12 In fact, chronic caffeine intake ameliorates oxidative stress and improves mitochondrial function in several neurotoxic situations. 13 A study in rats showed that caffeine reversed oxidative stress and attenuated inflammation induced by D-galactose, a compound that can induce aging in rat brains. 14 As well, caffeine increases glutathione S-transferase activity and inhibits red blood cell membrane derangement and apoptosis. 15, 16 It is also a strong scavenger of hydroxyl radicals. Therefore, the effect of caffeine in neurodegenerative disorders has been grossly investigated over the last decade. It has been shown that caffeine affects the pathophysiology of neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS),
Huntington's disease (HD) and Machado-Joseph disease (MJD). This review investigates the effects of caffeine on these neurodegenerative diseases, as well as the mechanisms involved.
| Caffeine, adenosine and adenosine receptors
As shown in Figure 1 , caffeine and adenosine have very similar basic structures. Both caffeine and adenosine have purine backbones, allowing for caffeine to also bind to adenosine receptors as a competitive antagonist of adenosine. 
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The interaction of adenosine with its receptors and the downstream effects are shown in Figure 2 . When adenosine binds to A 1 R and A 3 R, the inhibitory G-protein is activated, which inhibits adenylyl cyclase (AC) activation, reducing the conversion of AMP to cyclic AMP (cAMP), causing a decrease in protein kinase A (PKA) activation, leading to lower downstream phosphorylation. 20, 21 When PKA is not activated, calcium channels on the plasma membrane will not be phosphorylated, causing a reduction in calcium flow into the cell. However, when adenosine binds to A 2A R and A 2B R, the stimulatory G-protein is activated, increasing AC activity, cAMP and PKA levels and calcium entry into the cell. 20, 21 The binding affinities of adenosine to adenosine receptors and the K D (equilibrium dissociation constant) values for caffeine are shown in Table 1 . At 300 mg of consumption, caffeine affects all adenosine receptors, but it has the highest interaction with A 1 R and A 2A R.
| Adenosine A 1 receptor (A 1 R)
A 1 R is abundant throughout different parts of the brain, including the cerebellum and the cerebral cortex. 23 Adenosine, through the activation of the inhibitory A 1 R, acts as a neuromodulator in the nervous system that reduces neuronal excitability. 24 Targeted deletion of A 1 R gene does not produce any drastic changes in basal or caffeine-induced motor function, and therefore caffeine's effects on F I G U R E 1 The chemical structure of adenosine (left), an endogenous adenosine receptor agonist, and caffeine (right), an exogenous adenosine receptor antagonist 17 
F I G U R E 2
The interaction of adenosine with its receptors and the downstream mechanisms are outlined in this figure.
When adenosine binds to A 1 R and A 3 R, Gα i is activated, lowering AC activity, cAMP production, PKA activation, and calcium entry into the cell. When adenosine binds to A 2A R and A 2B R, Gα s is activated, increasing AC activity, cAMP production, PKA activation, and calcium entry into the cell. Gα i : inhibitory G-protein, Gα s : stimulatory G-protein, AC: adenylyl cyclase, cAMP: cyclic adenosine monophosphate, PKA: protein kinase A motor activity are not mediated by A 1 R inhibition. 23 However, chronic treatment, and blockade of these receptors, with caffeine causes an upregulation of A 1 R in rodents via an increase in the concentration of A 1 R. 7, 25 Interestingly, an increase in the expression of A 1 R causes a decrease in pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-α). 26 Direct evidence of the neuroprotective effects of inhibiting A 1 R has also been found in a model of methylmercury poisoning.
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| Adenosine A 2A receptor (A 2A R)
A 2A R is located mainly in the striatum, basal ganglia, olfactory cortex and the hippocampus. 23, 24, 28 These receptors are present pre-and postsynaptically and are also expressed on the glia. 29 Extracellular adenosine levels increase dramatically in response to ischemia, excitotoxicity, inflammation, and other brain insults. 30 A 2A R activation, via increased adenosine, protects against brain injury by modulating neurotransmission processes that are implicated in neuron-glia communication. As well, A 2A R is upregulated in microglia, where it potentiates the inflammatory cascade, 30 and hence its blockade offers robust protection against noxious brain conditions. 27 ultimate switch mechanism, meaning that high levels of adenosine will cause excitatory effects and low levels of adenosine will have inhibitory effects, as shown in Figure 3 . 32 Since caffeine does not allow adenosine to bind to the A 2A R, it abrogates the switch mechanism, resulting in less calcium influx into the cell and hence less glutamate release.
| Caffeine, phosphodiesterase and calcium release
Caffeine is a ryanodine receptor agonist. 33, 34 Ryanodine receptors are Ca 2+ releasing channels on the endoplasmic reticulum (ER). 35 Therefore, caffeine can increase the amount of calcium released from the ER by binding to and activating ryanodine receptors. 36 However, caffeine consumption at average dosages of 210-238 mg/d does not affect the ryanodine receptors. The levels of caffeine needed to initiate its effect on the sensitivity of ryanodine receptors are at plasma concentration of 100 μmol/L, which is equivalent to about 1520 mg/d of caffeine intake.
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Caffeine is an inhibitor of phosphodiesterase, which inactivates cAMP. 40 However, to inhibit phosphodiesterase, caffeine consumption has to be 20 times higher than the dose obtained from a single cup (100 mg of caffeine) of coffee, whereas to mobilize intracellular calcium depots it has to be 100 times higher.
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While modulation of phosphodiesterase and activation of ryanodine receptors may play a role in the effect of caffeine on Ca 2+ levels in neurodegenerative diseases, concentrations of caffeine needed to act on these are difficult to reach at nontoxic doses of consumption.
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| CAFFEINE AND ALZHEIMER'S DISEASE
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder that leads to cognitive, behavioral, and memory impairments. 42 The histopathological features of AD include: the extracellular depositions of diffuse and neuritic plaques that are composed of amyloid-β (Aβ) peptide, the intracellular accrual of neurofibrillary tangles that consist of hyperphosphorylated aggregates of the microtubule-associated protein Tau, and selective neuronal loss restricted to the hippocampus and the neocortex. 42, 43 Recently, caffeine has been of scientific interest because of its potential as an antioxidant compound, able to protect against oxidative stress in AD.
| Human studies
A 21-year follow-up study (875 women and 534 men, age 50 years at the beginning of the study) found that moderate consumption (3-5 cups, volume not identified) of coffee substantially reduced the risk of AD (62%-64%) and dementia (65%-70%) later in life, compared to low coffee consumers (0-2 cups). 11 The Canadian Study of Health and Aging, examining 10 263 men and women over the age of 65 years, observed coffee consumption to be associated with a 31% lower risk of AD in the Canadian population (OR=0.69, CI=0.5-0.96). 44 Another study found that 54 patients with AD had an average daily caffeine intake of 74±98 mg during the 20 years that preceded their diagnosis, whereas the age-matched controls had an average daily intake of 199±136 mg during the corresponding 20 years of their life. 45 50 In fact, caffeine-treated mice were significantly better in overall cognitive performance vs the APPsw control group. When administered in young adulthood (4-9 months) at similar doses, caffeine provided complete protection in all cognitive tasks that were previously impaired in APPsw mice. 7 Caffeine's protective effects were global, protecting the working memory, spatial learning, and recognition. 
| Caffeine reduces amyloid β production and increases amyloid β clearance
Caffeine's beneficial effects in AD are through its interaction with β-and γ-secretase. 51 In a study conducted in 2009, Arendash et al. 50 found that caffeine treatment at 1. 52 In fact, at plasma concentrations of 20±5.4 μg/mL (103±28 μmol/L), caffeine caused a 20% increase in Aβ clearance. However, it is important to note that this dosage is very close to toxic dosages of caffeine in humans.
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Another study found that crude caffeine treatment at human equivalence of 292 mg/d suppressed Aβ 1-42 levels (52%) and decreased plaque number (67%) in APPsw mice. 49 As well, Aβ-treated neurons exposed to crude or pure caffeine had reductions in the number of caspase-3 positive neurons of approximately 48% and 43%, respectively.
| Effect of caffeine on signaling pathways
Treatment with caffeine at 1.5 mg/d for 5.5 months in APPsw mice normalized PKA levels, otherwise downregulated in APPsw mice. 50 As shown in Figure 4 , PKA is responsible for inactivating c-Raf-1, which is responsible for activating NF-κB pathway, leading to the production of β-secretase-1 (BACE-1) and other AD-related proteins. Hence, caffeine consumption at doses equivalent to 500 mg in humans causes a reduction in c-Raf-1, NF-κB pathway activation, and BACE-1 production in APPsw mice. Furthermore, GSK-3 is known to regulate Aβ production.
It is also involved in presenilin (PS)-1 and γ-secretase activity as well as tau hyperphosphorylation; caffeine concentration at 10-20 μmol/L decreases the GSK-3α and GSK-3β, proposing a mechanism for decreasing Aβ levels. 50 Also, caffeine normalized PS-1 levels and caused a 50% reduction in BACE levels in young mice (4-9 months). 7 In human neuroblastoma cells treated with aluminum chloride (AlCl 3 ), pretreatment with caffeine (10 μmol/L) reduced phosphorylated IκBα and NF-κB levels and nuclear translocation of NF-κB down to control levels.
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In mice, caffeine treatment for 8 weeks (0.75 mg/d and 1.5 mg/d) normalized the reduced levels of brain-derived neurotrophic factor (BDNF) and its receptor (TrkB) responsible for growth, survival and neuronal cell differentiation. 53 The effects of caffeine on BDNF were dose dependent, increasing with higher doses of caffeine, but the same was not observed for the levels of TrkB. 53, 54 cAMP response element binding protein (CREB), a transcription factor associated with memory and neuronal survival, is downregulated in APPsw mice, but caffeine at 1.5 mg/d significantly increased CREB levels by 126%. 55 Caffeine also reduced the upregulated levels of pERK in the striatum (70%) and the cortex (59%) of APPsw mice down to normal levels.
| Caffeine reduces oxidative stress and apoptosis, through increasing antioxidant capacity
In human neuroblastoma cells, caffeine (10 μmol/L) lowered ROS production (51%) in the cells treated with Aβ and AlCl 3 , increased superoxide dismutase (SOD) levels (50%), and lowered malondialdehyde (MDA) levels (50%). 27 Also, pro-apoptotic Bax was upregulated and anti-apoptotic Bcl-2 was downregulated in the cells treated with Aβ and AlCl 3 , whereas pretreatment with caffeine normalized both protein levels. When these cells were treated with A 2A R-specific antagonist (10 μmol/L of SCH58261), cell death was prevented only partially;
however, caffeine treatment provided full protection, recognizing the important neuroprotective effects of A 1 R and A 2A R antagonism. 27 As well, a study showed that caffeine (0.6 mg/d) increased hippocampal mitochondrial respiration (25%) and ATP levels (46%) in the APPsw mice; and by a much greater degree, caffeine increased hippocampal mitochondrial membrane potential (78%) and decreased ROS production (100%). 56 As well, caffeine increased adenosine levels; adenosine is a vasodilator 57 responsible for increased blood flow to the brain, contributing to caffeine's protective effects. 
| Caffeine may reduce the risk of Alzheimer's disease in individuals carrying ApoE ε4 allele
Those who carry one or two copies of apolipoprotein E (ApoE) ε4
allele have an increased risk of developing AD. 58 ApoE is linked to cholesterol transport, because it carries cholesterol from the blood into the brain and shuttles cholesterol from astrocytes to neurons. 59 Therefore, presence of ApoE is associated with increased cholesterol levels. 60 Indeed, a recent epidemiological study reported that increasing levels of cholesterol were associated with an increased risk of AD, but only for individuals with the ApoE ε4 allele. 61 Hypercholestrolemia has been linked with oxidative stress, through the increased production of ROS. 59 Prasanthi et al. demonstrated that a 2% cholesterolenriched diet increased Aβ levels, tau phosphorylation, and oxidative stress in rabbit hippocampus. However, treatment with caffeine (0.5 and 30 mg) reduced Aβ production, tau phosphorylation, ROS generation, and glutathione depletion and increased the levels of A 1 R receptor. 59 Therefore, treatment with dietary antioxidants, such as caffeine, may be effective in reducing the risk of AD in individuals carrying the ApoE ε4 allele. Further research on the effect of caffeine in these individuals is warranted.
F I G U R E 4
Caffeine normalizes the otherwise reduced PKA levels in APPsw mice, therefore inhibiting c-Raf-1 activation, NF-kB pathway activation, and BACE-1 production, leading to lower levels of plaque formation 50 
| CAFFEINE AND PARKINSON'S DISEASE
Parkinson's disease (PD) is characterized by bradykinesia (slowness of movement), rigidity, and postural instability. 62 The etiology of PD is not fully understood, but it is thought to be the consequence of the loss of dopaminergic neurons of the substantia nigra pars compacta and striatum, resulting in deficit of striatal dopamine that leads to the impairment of the corticostriatal-thalamo-cortical or the nigrostriatal pathway of movement. 63, 64 Neuronal insult in PD is caused primarily by excessive oxidative stress, leading to damaged proteins, DNA, and lipids.
The majority of ROS are initiated from the inflammatory microglial cells, which are activated by certain inflammatory or genetic factors. 65 Convergent epidemiological and preclinical data suggest that caffeine can confer neuroprotection against the underlying dopaminergic neuron degeneration and can influence the onset and progression of PD. can cross the blood-brain barrier where it is taken up specifically by dopaminergic receptors. 65 There, it inhibits complex I of the electron transport chain, causing a severe energy crisis, leading to cell death and hence dopamine insufficiency in the striatum. 63 Accompanying the insult from MPTP, there is a peak in microglial proliferation, leading to severe neuroinflammation. Therefore, MPTP-induced damage is an excellent model of neurodegeneration in PD.
| Caffeine reduces MPTP-induced neuron damage in models of Parkinson's disease
Caffeine treatment at 30 mg/kg for 8 days (0.9 mg/d) 30 minutes prior to MPTP administration attenuated neuron damage and improved motor function (60.6% improvement in grip strength) in male PD mice. 63 Another study found that caffeine pretreatment attenuated MPTP-induced dopamine loss (38% of the control dopamine levels without caffeine) in a dose-dependent manner in young (10 weeks) male mice, with maximal effects achieved at 10 mg/kg (78% of the control dopamine levels with caffeine). 75 In old male mice (6-9 months), MPTP-induced dopamine loss (3% of control dopamine levels without caffeine) was attenuated by caffeine pretreatment in a dose-dependent manner, with 10 mg/kg of caffeine offering the most neuroprotective effect (~30% of control dopamine levels with caffeine). 75 In male Sprague Dawley rats, oral caffeine (1 g/L in drinking water) from the onset of MPP + infusions prevented the loss of nigral dopamine cell bodies. 
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When exposed to caffeine (10 mg/kg) 10 minutes before MPTP administration, the residual dopamine level in mice was 40% of the control, whereas without caffeine it was 15% of the control. 77 At 20 mg/ kg, caffeine nearly reversed the dopamine depletion caused by MPTP in mice, but at higher levels caffeine caused excessive systemic toxicity. 
| Caffeine may not be as effective in female Parkinson's disease models due to estrogen
In female mice, MPTP depleted striatal dopamine levels to 62% of the control, which is a much smaller reduction compared to their male counterparts, whose striatal dopamine levels were 38% of control. 75 However, Male mice treated with estrogen also experienced the neuroprotective effects of estrogen; however, no dose of caffeine attenuated their striatal dopamine loss. 75 Caffeine is largely metabolized by CYP1A2, which 
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Pathological hallmarks of this disease include the following: progressive muscle weakness, atrophy, and spasticity. 91 On a cellular level, excessive stimulation of glutamate receptors leads to a large influx of calcium ions into the postsynaptic neuron, resulting in oxidative stress, oxidative damage, inflammation, and apoptosis. 
| Human studies
In a meta-analysis incorporating five large cohort studies that examined 1 010 000 men and women (60 years) after an 18-year follow-up, caffeine was found not to be associated with the risk of ALS; the results were similar among men and women. 92 None of the participants were mouse model of ALS. 88 Adenosine levels are upregulated in the
Caffeine is metabolized by CYP1A2, which also metabolizes estrogen. Therefore, metabolism of estrogen has an inhibitory effect on metabolism of caffeine 72, 82 cerebrospinal fluid of progressing human ALS patients, perhaps partially due to upregulated AMPK levels in ALS. 
| Caffeine may inhibit Riluzole clearance
Riluzole is the only licensed drug for ALS, and its mechanism of action is through the inhibition of the deleterious effects of an overload of glutamate and other neurotransmitters in the CNS. 94 Riluzole is rapidly absorbed, with maximum concentration 1-2 hours after administration. Its elimination is assumed to be mainly through oxidative metabolism by the CYP1A2 enzyme. There is a significant positive ratio between the expression of CYP1A2 and the clearance of Riluzole. 94 Caffeine, another substrate of the CYP1A2 enzyme, prevents N-hydroxylation of Riluzole via CYP1A2. 95 Therefore, although some studies suggest a lack of correlation between ALS risk and caffeine consumption, the effect of caffeine in ALS should be further investigated, especially with the concomitant intake of Riluzole.
| CAFFEINE AND HUNTINGTON'S DISEASE
Huntington's disease (HD), an inherited neurodegenerative disorder caused by expanded CAG repeats, is characterized by motor, cognitive, and psychiatric disturbances. 
| Human studies
One study showed that in 80 HD male and female patients (50 years), caffeine consumption at >190 mg/d in the last 10 years was associated with a 1.6 years earlier age of onset of HD. 
| Caffeine treatment reduces oxidative stress through increasing antioxidant capacity
In QA administered rats, treatment with caffeine 40 mg/kg for 21 days restored MDA, nitrite, and SOD levels back to levels of the healthy control rats. 13 At 10 mg/kg and 20 mg/kg, caffeine reduced the levels of MDA (15% and 42%, respectively) and nitrite (5% and 11%, respectively) and increased the levels of SOD (19% and 62%, respectively) and catalase (19% and 65%, respectively). Therefore, caffeine administration significantly reduced oxidative stress in QA-treated rats by increasing endogenous antioxidant capacity and decreasing oxidative damage in a dose-dependent manner. Administration with QA reduced the levels of complex I, II, and III in the mitochondria, but treatment with caffeine (40 mg/kg) restored these levels. 
| High dosages of caffeine, as well as adenosine
| CAFFEINE AND MACHADO-JOSEPH DISEASE
Machado-Joseph disease (MJD) results from an increase in the number of CAG codon repeats. It is characterized by an adult age of onset and causes premature death associated with unstable expansion of CAG stretch in the MJD1 gene that encodes polyQ repeat in the corresponding ataxin-3 protein. 100 The clinical hallmarks of the disease are progressive ataxia (loss of control of bodily movements), dysfunction of motor coordination, postural instability, and parkinsonism.
Glutamate overstimulation promotes the proteolysis and aggregation of ataxin-3. 101 One study showed that chronic caffeine consumption and genetic A 2A R deletion reduced progressive degeneration, neuronal death, neuronal dysfunction, and reactive gliosis, sequestered noxious ataxin-3, and prevented ataxin-3-induced synaptotoxicity.
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Further studies need to explore the effects of caffeine in MJD, at different doses and in men and women.
| CAFFEINATED AND DECAFFEINATED COFFEE
Several studies have shown that decaffeinated coffee is not associated with the risk of developing neurodegenerative diseases.
70,92,103
For example, Arendash et al. found that plasma Aβ levels did not decrease with administration of decaffeinated coffee to AD mice, suggesting that caffeine is critical to decreasing plasma Aβ levels in AD.
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As well, several studies have shown that consumption of decaffeinated coffee is not associated with the risk of PD. 51, 64, 70, 74 One study investigating the effects of caffeine and ALS also found no effect of decaffeinated coffee on the risk of developing ALS. 92 However, other studies show that the protective effects of caffeinated coffee are also present in decaffeinated coffee in non-neurodegenerative diseases, suggesting a major role of other compounds (polyphenols) in coffee.
For example, decaffeinated coffee consumption, as well as caffeinated coffee, had protective effects against heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections in 229 119 men and 173 141 women. 104 
| LIMITATIONS
The 
| FUTURE DIRECTIONS
Epidemiological studies have shown that caffeine consumption is associated with lower risk of developing AD in both men and women. As well, studies in animal models have shown that caffeine has protective effects against oxidative stress, inflammation, and apoptosis. Clinical studies need to investigate the effective, nontoxic, therapeutic dosage of caffeine for patients with AD. Furthermore, studies in humans and mice showed that caffeine administration prior to the onset of AD is beneficial. Hence, clinical studies should aim to investigate caffeine's efficaciousness in those at higher risk of developing AD, prior to diagnosis.
It is important to note that the dosages administered in mice resulted in plasma concentrations near toxic levels. Attention should be given to studying caffeine's influence on AD at average consumption levels.
Epidemiological and animal studies have ascertained the beneficial effects of caffeine on the development and progression of PD. Clinical studies need to confirm these findings. Some epidemiological studies showed that PD is inversely associated with caffeine consumption Meta-analysis found that caffeine intake from coffee or tea was not associated with the risk of cognitive disorders. May be due to type II error. One epidemiological study showed that caffeine consumption at levels >190 mg/d is associated with a higher risk of developing HD.
Alzheimer's disease-in vitro and in vivo animal studies Reference
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Main results
Conclusion
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However, studies in animal models show caffeine can restore motor function. 13 The discrepancy between the epidemiological and animal studies needs to be further investigated. Perhaps, caffeine has neuroprotective effects at different dosages. Further research needs to educate us about the exact therapeutic dosage of caffeine in the CNS.
Additional animal studies examining the effect of caffeine on HD may delineate caffeine's exact mechanism of action in this disease model.
This may then inform us further about caffeine's effect on the brain and motor performance in HD.
In terms of MJD, epidemiological studies are needed to advise us on the chronic effects of caffeine consumption on disease development and/or progression. Also, more studies are needed in animal models to understand caffeine's underlying mechanisms associated with MJD. Currently, no conclusion can be drawn about caffeine's effect on MJD, but the results are encouraging.
Caffeine is associated with reduced pain through its inhibition of the adenosine receptors, namely A 2A R. 29 Chronic caffeine treatment is associated with the upregulation of A 1 R, which is associated with reducing pain. 25, 29 PD and ALS are both associated with higher levels of pain, and hence caffeine's pain-reducing effects may contribute to improving these patients' quality of life and warrant further investigation. 105, 106 Caffeine can also enhance exercise performance in healthy individuals, 107 due to its stimulatory effects and its pain-reducing Caffeine has a potential beneficial role in preventing AD in those exposed to aluminum.
T A B L E 2 (Continued)
T A B L E 3 Summary of the human epidemiological studies and the in vitro and in vivo animal studies investigating the effect of caffeine on Parkinson's disease (PD) There is a potential neural basis for the neuroprotection effects of caffeine in PD.
Parkinson's disease (PD)-human epidemiological studies Reference
Participants
Duration
Main results
Conclusion
Xu et al., 2006
C57BL6 mice n=3-7 saline treatment n=4-15 MPTP Females and males Young: 10 wk Old: 6-9 mo 10, 20, 40 mg/kg of caffeine treatment Caffeine administration 10 min before MPTP administration Caffeine: ↓ MPTP-induced dopamine loss (38% of the control dopamine levels) in a dose-dependent manner in young male mice, with maximal effects achieved at 10 mg/kg (78% of the control dopamine levels with caffeine).
In old male mice, MPTP-induced dopamine loss (3% of control without caffeine) ↓ by caffeine pretreatment in a dose-dependent manner, with 10 mg/kg of caffeine offering the most neuroprotective effect (~30% of control with caffeine).
In female mice, caffeine ↓ toxicity only at 40 mg/kg. In ovariectomized mice treated with placebo (striatal dopamine 27% of control), caffeine at 5, 10, 20 mg/kg was neuroprotective.
In ovariectomized mice treated with estrogen (striatal dopamine 39% of control), caffeine was neuroprotective only at higher doses (40 mg/kg).
In males treated with estrogen, estrogen was neuroprotective, but caffeine in these mice did not attenuate their striatal dopamine loss.
Estrogen can prevent the neuroprotective effects of caffeine in a model of PD mice.
Nakaso et al., 
Conclusion
Amyotrophic lateral sclerosis-human meta-analysis study Fondell et Caffeine consumption over the past 10 y of the patients' lives was assessed, in a self-survey. Caffeine consumption (>190 mg/d) → 1.6 y earlier age of onset of HD.
Caffeine consumption at higher dosages may be associated with earlier age of onset for HD.
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Conclusion
Huntington's disease-in vivo animal study Mishra et al., 2014 Sprague Dawley rats n=8 for each group Males and nitrite (5% and 11%, respectively), and ↑ SOD (19% and 62%, respectively) and catalase (19% and 65%, respectively).
QA ↓ complex I, II, and III in the mitochondria, but caffeine (40 mg/ kg) ↑ these levels.
Caffeine significantly reduced the oxidative stress in QA-treated rats by increasing endogenous antioxidant capacity and decreasing oxidative damage, in a dosedependent manner.
Machado-Joseph disease-in vivo animal study Gonçalves et al., 2013 C57BL6 mice n=6 caffeine n=5 water mechanisms. Caffeine may also enhance the ability to partake in daily activities and improve quality of life for PD, ALS, HD, and MJD patients. Focus needs to be directed toward examining caffeine's potential to improve the quality of life in patients with neurodegenerative diseases with respect to mobility and functional outcomes. 
| CONCLUSION
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